Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
Jon T GilesAlexis OgdieJuan J Gomez ReinoPhilip S HelliwellRebecca GerminoLori StockertPamela YoungWael JosephRajiv MundayatDaniela GrahamChristopher T RitchlinPublished in: RMD open (2021)
Tofacitinib demonstrated greater efficacy than placebo in patients with PsA, regardless of baseline BMI. For all treatment arms, reduced efficacy was observed in patients with baseline BMI ≥35 kg/m2. Safety was generally comparable across BMI categories, although the effect of tofacitinib on liver enzymes in patients with baseline BMI ≥35 kg/m2 was inconclusive.